ProVerum Medical

Executive Summary

ProVerum Medical is an Irish medical device company developing the ProVee stent, a novel treatment for Lower Urinary Tract Symptoms (LUTS) caused by benign prostatic hyperplasia. The ProVee stent utilizes a unique 3-D geometry that mirrors the prostate anatomy, opening the prostatic urethra and applying radial force to the prostatic lobes to alleviate symptoms. As a private, early-stage company founded in 2016, ProVerum is focused on clinical validation and regulatory approvals to bring its device to market. The company's technology has the potential to offer a less invasive alternative to current treatments, which include medication and surgery, by providing a temporary or permanent implant that preserves the natural urethral anatomy. While financial and operational details remain limited, the device's differentiated design suggests a competitive advantage if clinical trials demonstrate safety and efficacy. However, the lack of disclosed funding rounds or commercialization milestones underscores the early-stage risk. ProVerum's success hinges on successful clinical outcomes, regulatory clearance (e.g., CE mark or FDA 510(k)), and adoption by urologists and patients. The company's location in Galway benefits from Ireland's medtech ecosystem but faces challenges from established players and reimbursement hurdles.

Upcoming Catalysts (preview)

• TBDClinical trial results for ProVee stent40% success
• Q3 2026Regulatory submission (CE mark or FDA 510(k))35% success
• TBDPartnership or strategic investment for commercialization30% success